JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us
このページは機械翻訳されています。他のページは英語で表示される場合があります。 View in English

肺がん患者の肺循環に対する免疫チェックポイント阻害剤の効果

  • 0Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
International Journal of Cancer +

|

2025年9月6日

|

2025年9月6日

PubMedで要約を見る

まとめ

この要約は機械生成です。

免疫チェックポイント阻害剤 (ICI) は,肺がん患者の肺血管の変化を引き起こし,3ヶ月以内に胸部CTで検出できます. これらの変化は生存に影響を及ぼし,ICI治療中のモニタリングの必要性を強調しています.

科学分野

  • 心臓病科
  • 腫瘍学
  • 放射線科

背景

  • 免疫チェックポイント阻害剤 (ICI) は重要ながん治療法ですが,免疫関連の有害事象 (irAEs) を引き起こします.
  • 特に肺がん患者の心臓血管構造への影響を理解することが必要である.

研究 の 目的

  • ICI治療を受けている肺がん患者の肺動脈直径 (PAD),大動脈直径 (AoD),およびその比率 (PAD/AoD) の変化を調査する.
  • これらの血管の変化,心臓のバイオマーカー,および患者のアウトカム (全生存率および無進行生存率) の間の相関を評価する.

主な方法

  • ICIで2年間治療された461人の肺がん患者による遡及コホート研究.
  • PAD,AOD,PAD/AOD比を測定するために,複数の時間点 (ベースライン,3ヶ月,6ヶ月,1年,2年) での胸部CTスキャンを分析する.
  • 心臓のバイオマーカー (hs- TnI, HBDH, CK, CK- MB) と凝固指数の評価; 心臓の超音波検査も行われました.

主要な成果

  • ICI治療の3ヶ月以内にPAD (25. 19から26. 33mm) とPAD/ AOD比 (0. 70から0. 73) の有意な増加が観察されました (p < . 001).
  • hs- TnI,HBDH,CK,CK- MBの上昇と凝固指数の変化 (p < 0. 05) が認められたが,心臓の超音波検査では有意な変化は見られなかった.
  • 重度のPAD/ AOD比の進行は,全生存期 (43 vs. 56ヶ月) と進行性生存期 (15 vs. 20ヶ月) の低下と関連していた (p < .008).

結論

  • PAD/AoD比の変化によって示される肺血管再構成は,ICIを受けている肺がん患者で早期 (3ヶ月以内) に起こります.
  • PAD/AoD比の進行は,この患者群における不良予後を予測する独立した要因である.
  • 肺がんのICI治療中に胸部CTによる肺血管変化のモニタリングが推奨されます.

キーワード:

関連する概念動画

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications. 01:25

2.9K

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

• Chronic Cough: A persistent cough, often productive, is a crucial symptom of COPD.
•...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers 01:26

250

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Tumor Immunotherapy 01:27

658

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Pulmonary Embolism I: Introduction 01:29

45

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...

Cancer Therapies 02:49

7.9K

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

COPD: Pathogenesis and Clinical Features 01:20

512

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...